Pediatric Blood & Cancer · 20 Nov 2026
Late Effects of 131 I‐MIBG in Survivors of High‐Risk Neuroblastoma: A Report From the Children's Oncology Group LEAHRN Study
Prerna Kumar, Maggie Cupit‐Link, Sara M. Federico, Jenna K. Bardwell, Steven G. DuBois, Pei‐Chi Kao, Wendy B. London, Lisa R. Diller, Tara O. Henderson
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
ABSTRACT Background Meta‐iodobenzylguanidine radiolabeled with iodine‐131 ( 131 I‐MIBG) is used to treat high‐risk neuroblastoma (HRNBL). Late toxicities of 131 I‐MIBG have not been well studied due to limited survival of patients receiving this therapy for relapsed disease. Methods The Children's Oncology Group LEAHRN study evaluated HRNBL survivors diagnosed after 2000 and alive at least 5 years from diagnosis. Clinical history and the prevalence of late effects were summarized for participants treated with 131 I‐MIBG (cases). Participants who did not receive 131 I‐MIBG were randomly selected and matched by age at diagnosis and relapse history (controls) in a 1:2 case–control study design. Chi‐squared analysis was used to evaluate the association between 131 I‐MIBG and late toxicities. Results Of 375 participants in the LEAHRN analytic cohort, 32 (8.5%) received 131 I‐MIBG. Differences in the proportion with thyroid toxicity and growth failure were observed but not statistically significant. The proportions of other major organ toxicities were not different between cases and controls, including subsequent malignancy. Discussion No statistically significant differences were identified in the burden of late toxicities for HRNBL survivors treated with and without 131 I‐MIBG. A small sample size likely limited the ability to detect statistically significant differences. Our data provide information for follow‐up care of 131 I‐MIBG‐treated survivors and clinical trial design.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (14)
What it cites, from open citation data, with Crossref's record of each.